Chronic lymphocytic leukemia (CLL)-B-cells are quiescent differentiated cells that produce interleukin (IL)-10 and accumulate due to resistance to apoptosis. The mechanisms underlying such resistance are poorly understood. Herein we show that all CLL B-cells tested (30/30) display high mRNA and protein expression of the tumor suppressor Mda-7/IL-24, an IL-10 family member, in comparison to normal B cells. A downstream Mda-7 signaling target, p38 mitogen-activated protein kinase (MAPK) was highly phosphorylated in all CLL cells but not in normal B-cells. Mda-7 expression and p38 MAPK phosphorylation diminished in culture and the latter could be reinduced by recombinant (r)-IL-24 or LPS and Mda-7 transfection. Mda-7/IL-24 siRNA specifically inhibited p38 MAPK phosphorylation in CLL without affecting p38 MAPK, bcl2, or Lyn expression, further demonstrating the direct role of Mda-7/ IL-24 in p38 MAPK activation. Both pharmacological inhibition of p38 MAPK and Mda-7 silencing augmented spontaneous apoptosis by three-fold in CLL cells cultured in autologous serum, which was reversed by LPS and r-IL-24. We established the role of p38 MAPK in CLL cell survival and demonstrated a paradoxical effect, whereby Mda-7 and IL-24, inducers of apoptosis in diverse cancer cells, promote the survival of CLL B-cells through p38 MAPK activation.
Introduction

B-cell chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of circulating CD5
þ monoclonal B-cells. 1, 2 These cells contrary to normal B-lymphocytes are refractory to activation by mitogens, 3, 4 and have quantitative and qualitative deficiencies in the B-cell receptor (BCR) expression and signaling. 1, 2, 5, 6 As a consequence, these cells display a resting phenotype, often respond poorly to activation and are mostly in G0/early G1 phase of the cell cycle, 7-9 a characteristic that may protect them from drugs-and activationinduced apoptosis. 10 CLL cells have been considered as anergic although this may be especially true for those with mutated IgV genes. CLL B cells have membrane markers of mature antigen-experienced cells. 11 Moreover, in up to 70% of cases, their mutational status within Ig V regions suggest that they have passed through germinal centers. 12 In addition, their mature phenotype associated with a low BCR expression suggest that they have been submitted to a chronic stimulation with auto-antigen, a condition shown to induce anergy, 13 and CD5 expression on B-cells in experimental models.
14 Whether CD5 plays a role in CLL B-cell survival is not yet clear. We have however observed that, contrary to the majority of CD5
À B cells, normal CD5 þ blood B cells displayed a low Ca 2 þ response following anti-IgM stimulation, 15 confirming the role of CD5 as a negative regulator of BCR signaling. 16, 17 Even though BCR-mediated activation is often deficient in CLL, CD5 may act independently of the BCR by recruiting signaling molecules, 18, 19 and eliciting the production of B-cell survival factors such as interleukin (IL)-10. 15 IL-10 is indeed produced by most CLL B-cells, 20 improves the survival of malignant CLL B-cells, 21 and IL-10 serum levels in CLL correlated with the severity of the disease. 22 We compared mRNAs from vector-and CD5-transduced Daudi cells, 15 by means of Affymetrix DNA chips. We found that all IL-10 family genes, 23 and receptors were upregulated in CD5-transfected vs vector-transfected Daudi cells (article in preparation). Among these cytokines, IL-24, 24 is an alternative transcript of Mda-7, a gene encoding a melanoma differentiation antigen that functions as a tumor suppressor in the context of cancer cells. 25 We confirmed by real-time PCR the augmented expression of Mda-7/IL-24 transcripts in CD5 þ Daudi cells, and in the CD5 þ B-cell population from normal adult blood in comparison to CD5-negative B-cells. Our DNA chips data were also validated by RT-PCR for IL-10, IL-19 and IL-20. 23 Mda-7/IL-24 mRNA expression in CLL was more than 10-fold that in normal B-cells and a positive correlation between CD5 and Mda-7/RNA expression was found on randomly analyzed CLL samples. This prompted us to study the function of Mda-7/IL-24 in CLL. We show herein that this gene acts as a survival factor in part through phosphorylation of the p38 mitogen-activated protein kinase (MAPK) protein and the importance of this latter pathway in CLL is highlighted in this work.
Materials and methods
CLL samples
Blood samples from patients (22 treated, eight untreated) and 18 samples from healthy donors were processed after they had given informed consent to the Pitié-Salpêtrière university hospital. Patients were 18 males and 12 females, with ages ranging from 49 to 87 years old and lymphocyte counts ranging from 3940 to 113 000/mm 3 , with % lymphocytes/PBMC ranging from 32.6 to 97% PBMC were isolated by density centrifugation and B-cells were negatively selected as described. 15 
Cell culture and reagents
Daudi cells and PBMC from healthy donors and patients were cultured in RPMI medium supplemented with 10% FCS or 10% autologous serum, Penicilline (100 U/ml), Streptomycine (100 mg/ml), 2 mM L-glutamate and 1 mM sodium pyruvate (Invitrogen, Cergy, France). Cells were incubated with r-IL-2, r-IL-24, (all from R&D systems, Lille, France) at respective final concentrations of 50 ng/ml and 100 ng/ml. Affinipure F(ab 0 ) 2 polyclonal Rabbit anti-human IgM (Jackson Immunotech, West Grove, USA) was used at 2 mg/ml and LPS from Escherichia coli (VWR International SAS, Fontenay sous bois, France) was used at 10 mg/ml. SB 203580 in solution (lot#B64038) (Calbiochem) was used at doses ranging from 1 to 20 mM. For apoptosis studies, cells were stained with the Apo 2.7 mAb (BeckmanCoulter, Villepinte, France). Real-time PCR and Mda7 gene nomenclature Cells (2 Â 10 6 /ml) were incubated in complete medium for 24 h under various conditions, and RNA purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was carried out with random hexamers using Superscript first-strand synthesis system for RT-PCR (Invitrogen). Transcript expression was analyzed by PCR using the TaqMan technology. Results were analyzed using the ABI Prism 7700 sequence detection system software (PE Applied Bio System). Each reaction was normalized by the cycle threshold (Ct) of GAPDH cDNA expression. Relative expression was calculated by measuring the difference of normalized Ct between condition A vs condition B and applying the following formula: difference of expression between A and B ¼ 2eÀ(CtAÀCtB). The following TaqMan specific primers and probes were selected using Primer Express Software (PE Applied Biosystems) and specificity verified using NCBI Blast software:
Cell lines and RT-PCR
Mda 
Western blots
CLL cells were processed from fresh blood and washed at room temperature in a serum-free RPMI-10 mM HEPES. Cells (2 Â 10 6 Daudi, or 10 7 PBMC or CLL) were lysed at 41C for 30 min in lysis buffer (20 mM Tris-Hcl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 50 U/ml aprotinin, 1 mM PMSF, 1 mM sodium orthovanadate) containing 1% nonidet-P-40 detergent. 60 mg proteins/sample were separated on SDS-PAGE gels under reducing conditions, electrotransferred onto PVDF membranes (Amersham), and blotted with antiphospho-p38 MAPK (T180/Y182) rabbit polyclonal antibody (R&D) then with anti p38 MAPK mAb (A-12, Santa-Cruz, Heidelberg, Germany) after stripping. Mda-7/IL-24 proteins were blotted with anti-human IL-24 mAb (R&D). Mouse mAb IgG anti Bcl2 and Rabbit polyclonal anti-Lyn were from Santa Cruz. Blots were revealed using Goat-anti-Mouse or Goatanti-Rabbit HRP-conjugated (Bio-Rad Lanoratories) and ECL detection (Amersham).
Deglycosylation of IL-24
In total, 25 ng of human rIL24 (R&D) were diluted in 35 ml deionized water, 10 ml of 5 Â reaction buffer pH 7.5 (250 mM sodium phosphate) and 2.5 ml denaturation solution (2% SDS, 1 M b-mercaptoethanol) were added to the mixture, heated 10 min at 1001C, and 2.5 ml Triton X-100 (15% solution) þ 2.5 U of peptide-N-glycosidase F (Sigma, 500 U/ml) added for 3 h at 371C and inactivated 5 min at 1001C.
ELISA
For IL-24 detection, 96 well flat-bottom plates were coated overnight with an anti-IL-24 mAb (R&D) (100 ml at 2 mg/ml) in Na carbonate coating buffer, washed with PBS, 0.05% Tween-20, incubated for 1 h at RT with a blocking buffer (PBS, 1% BSA, 0.2% Tween-20), and washed. Serial dilutions of rh IL-24 (R&D), or serum (100 ml/well) from patients or controls were added for 2 h at RT. HRP-streptavidin (Biogenex, San Ramon) was added for 30 min, at RT. Reaction was developed by adding ABTS (Roche, Meylan, France) in the dark for 10 min, and stopped with 1 N H 2 SO 4 . The OD was red at 450 nm (Beckman Coulter, Villepinte, France). Detection of IgG in sera was performed with a human IgG ELISA detection kit (Interchim, Montluçon, France).
Statistical analysis
All statistics were carried using the Mann-Whitney U-test.
Results
High expression of Mda-7 and IL-24 mRNA in CLL B-cells
We analyzed IL-24 and Mda-7 transcripts in several B-cell types by conventional and real-time PCR. IL-24 arises from Mda-7 through alternative splicing of Exon 1a (Figure 1a) . Two sets of primers and internal probes were used, the first one located within exon 1a and another one at the 3 0 UTR region of the transcript, specific for Mda-7 only or for both Mda-7 and IL-24, respectively ( Figure 1a) . The expression of mda-7/IL-24 mRNA was augmented upon introduction of CD5 into Daudi B cell line (Po0.05) in keeping with our previously observed CD5-induced IL-10 expression. 15 Mda-7/IL-24 mRNA were higher in normal adult blood B cells than in Daudi cells (Po0.01), and were augmented 2.5-fold in the CD5 þ B-cell population. Most importantly, Mda-7/IL-24 expression in 30/30 fresh CLL B cells was augmented 10-fold as compared to normal blood B cells (Po0.001) (Figure 1b) . To show that both Mda-7 and IL-24 transcripts were expressed in CLL, a set of primers located outside exon 1a was used to amplify this region generating 365 bp in exon1a-negative (IL-24) and 518 bp PCR products in exon 1a-positive (Mda-7) PCR products, respectively (Figure 1c 
Characterization of Mda-7/IL-24 protein and IL-24-receptor expression in CLL
We investigated the presence of Mda-7/IL-24 protein in lysates from various B-cells by SDS-PAGE followed by Western blot. The protein was undetectable in Daudi cells, and weak or undetectable in PBMC and purified B cells from normal blood (Figure 2a) . By contrast, it was always positive albeit with variable intensity on all (30/30) CLL samples tested as shown from a representative panel of three patients (Figure 2a) . In CLL, the Mda-7/IL-24 mAb recognized predominantly a 20 kDa protein and higher molecular forms were present, whereas control r-IL-24, migrated as a single 35 kDa band reflecting the glycosylation of the recombinant cytokine. Indeed, in vitro deglycosylation with the endoglycanase, PNGase F 26 restored the 20 kDa protein size (Figure 2a left) . Thus, CLL express Mda-7/IL-24 protein in a predominantly nonglycosylated form. IL-24 and IgG as control were measured by ELISA in the sera of 30 patients and 18 healthy blood donors. IL-24 was undetectable in patient's sera at variance with 2/3 of control sera in which 4100 ng/ml were detected by average (Figure 2b) .
IL-24 receptors are heterodimers composed of a common IL20-R2 chain associated to either IL20-R1 or IL22-R chain. 26 The presence of receptors in CLL was investigated by RT-PCR specific for the three chains, respectively, and was evidenced in 
p38 MAPK is phosphorylated in fresh CLL cells and activated by rIL-24 and by Mda7
Some of the Mda-7/IL-24-induced signaling events were previously characterized in various non-B cell types using Mda-7-adenoviral infection and GST-Mda-7 fusion proteins, and include induction of p38-MAP kinase activation. 27 Transient introduction of IL-24 or Mda-7 cDNAs into Daudi B-cells (Figure 4a ) did not modify total p38 MAPK expression but enhanced p38 MAPK phosphorylation in comparison to empty vector-transfected cells (Figure 4a ). This effect is due to intracellular IL-24 and Mda-7 proteins since Daudi cells lacked IL-24R (Figure 3) ruling out an autocrine effect of secreted IL-24. We therefore investigated the p38 MAPK phosphorylation status in malignant cells. Western blots were performed and membranes incubated with anti-phospho-p38MAPK, stripped and reprobed with anti-p38 MAPK antibody. Phosphorylated p38-MAPK protein predominated in all fresh CLL cells by contrast to normal B cells, (Figure 4b ). Kinetic analysis of p38 MAPK protein expression showed that the phosphorylation of p38-MAPK gradually diminished in culture (Figure 4c and d) although the amount of total p38 MAPK was constant overtime. Mda-7/IL-24 expression also diminished in culture (Figure 4c ). The phosphorylation of p38 MAPK protein could be reinduced by r-IL-24 and by the canonical p38 MAPK activator LPS. 28 Forced expression of Mda-7 also augmented p38 MAPK phosphorylation in CLL in comparison to empty vectortransfected cells (Figure 4d) .
A direct evidence of Mda-7/IL-24-driven p38 MAPK activation in CLL was therefore needed and could be obtained by silencing Mda-7/IL-24 expression using Mda-7-specific siRNA. Cell scatter was comparable in both control and Mda-7-transfected samples. As shown in Figure 4e , we were able to transfect fresh CLL cells with a high 480% efficiency. At day 3, Mda-7/IL-24 protein expression became almost undetectable in Mda-7/IL-24-but not in control siRNA-treated cells. In parallel, the amount of p38 MAPK protein was comparable in Mda-7/ IL-24 and in control siRNA-treated cells, whereas phosphorylated p38 MAPK diminished in Mda7-silenced cells but not in control cells. Moreover, silencing did not affect the amount of other important proteins in CLL such as Bcl2 or Lyn pointing to the specific effect of endogenous Mda-7/IL-24 on p38 MAPK pathway.
The role of p38 MAPK activation in CLL survival
The finding of a significant phosphorylated MAPK fraction in fresh CLL cells suggested that p38 MAPK activation was not harmful. Whether its inhibition is detrimental was therefore investigated. We cultured all CLL samples in medium with 10% autologous serum to minimize spontaneous apoptosis, and assessed cell death by staining with the mitochondrial marker Apo 2.7. 29 FACS analysis was performed at days 4 and 7. Addition of SB 203580 at 10 mM to the culture induced cell death in all samples tested as early as day 4 as reflected by the cell-size decrease on cell scatter plot and a nearly three-fold increase in apoptotic cell numbers on histogram (Figure 5a ). In total, 12 samples from patients were cultured with or without r-IL-24, LPS, SB 203580 and theophylline. SB 203580-mediated apoptosis was reversed by LPS and by r-IL-24, whereas LPS or r-IL-24 alone did not protect cells from spontaneous death (Figure 5b cell death. Another evidence is that the apoptosis induced by theophylline in vitro 29 was not antagonized by r-IL-24 further pointing to the specificity of p38 MAPK in CLL survival. To definitively demonstrate the effect of intracellular Mda-7/IL-24 protein, apoptosis was studied in the three patients samples in which the protein could be efficiently silenced. As shown (Figure 5c ), apoptosis was augmented in all three experiments in Mda-7/IL-24 siRNA-silenced cells as compared to control cells cultured for 7 days in medium þ autologous serum. Furthermore, r-IL-24 and LPS protected cells against Mda-7/IL-24 siRNA induced cell death. Thus, endogenous Mda-7/IL-24 protein mediated its effect -at least partly -through p38 MAPK phosphorylation.
Discussion
We have shown here that CLL B-cells constantly express high amounts of the tumor suppressor Mda-7/IL-24 protein and of Mda-7 and IL-24 mRNA. The strong Mda-7/IL-24 expression in highly differentiated/activated CLL B-cells is reminiscent of what was observed in terminally differentiated melanocytes. 25, 27 Our failure to detect the protein in serum may be due to a dilution effect by nonsecreting malignant cells that express the receptors and should be able to internalize the cytokine. Alternatively, malignant cells may inhibit the production of IL-24 by normal mononuclear cells. If so, a deficit in IL-24, a pro-TH1 cytokine, 26 may contribute to the functional T-helper and dendritic cell deficits in CLL. 30 p38 MAPK is an important intermediate for the function of Mda-7, and is activated by endogenous Mda-7/IL-24 protein or by exogenous IL-24 in CLL. p38 MAPK can be proapoptotic in tumor cell lines, 25, 27 meanwhile it is constitutively active in normal liver cells. 31 It is obvious that phospho-p38 MAPK has no proapoptotic function in CLL since it is present in fresh cells, and is instead needed for the survival of malignant cells as inferred from the induction of apoptosis by the MAPK inhibitor SB 203580 and by Mda-7/IL-24 silencing, the latter which inhibited p38 MAPK phosphorylation. Addition of SB 203580 inhibited IL2-mediated cell proliferation in a dose-response manner, with a 50% inhibition of thymidine incorporation at 2.5 mM (data not shown), whereas apoptosis was detectable at Mda-7/IL-24 and p38 MAP kinase activation in CLL A Sainz-Perez et al higher (45 mM) concentrations. The importance of p38 MAPK in CLL survival is highlighted by the protective effect of IL-24 and LPS on SB 203580-mediated apoptosis, inasmuch as LPS induces IL-24 production by PBMC. 24 Our results confirmed the previously published data demonstrating that p38 MAPK is constitutively active and exerts a protective role in CLL. 32 We cannot totally exclude that IL-24 works also through a p38MAPK-independent mechanism; however, our data suggested a competition between IL-24 and SB 203580 for p38 MAPK activation as evidenced by sequential incubations. Indeed, IL-24 augmented p38 MAPK phosphorylation when added several hours after SB 203580, suggesting that the inhibitory effect of this drug is reversible (data not shown).
p38 MAPK is an important regulator of cell cycle and survival in CLL, possibly through direct interaction with, and phosphorylation of p53 at specific serine sites. 33 p38 MAPK activation by IL-24 and other factors, such as TGF-b, 34 may also contribute to anergy in CLL similarly to that demonstrated in T cells. 35 Since Mda-7 promoted cell survival, it could be expected that its expression level correlates with the clinical/biological status in CLL, and a quantitative study of Mda-7 and phospho-p38 MAPK should be carried out, although in preliminary studies we failed to observe a difference between Ig-mutated vs unmutated patients. The same question should be addressed for CD5. Our results suggested that CD5 induced Mda-7 in CLL; however, a direct demonstration was not obtained due to our failure to efficiently silence CD5 either by RNA interference or in culture with Cyclosporine-A or IL-4, which reversed the PMA-induced CD5 increment, but did not affect its basal level in malignant cells.
In CLL, the BCR repertoire of malignant cells is suggestive of selection by antigen. 11 A chronic stimulation likely induces CD5 expression and cell anergy. 15, 16 We therefore propose that CLL permanent triggering in vivo results in the upregulation of genes such as CD5 and Mda-7/IL-24, the latter activating p38 MAPK and inhibiting cell death. This suggests that CD5 silencing should be detrimental for CLL survival. In support of this, CD5 ligation induced apoptosis in a CLL subgroup, possibly by uncoupling CD5 from the BCR or from BCR-associated signaling molecules. 36 We have been able to silence gene expression in CLL with a fairly good efficiency. This technology will allow us to study the role of selected molecules, upstream of p38 MAPK on the survival of malignant cells. In total, 12 CLL samples from distinct patients were cultured in medium þ autologous serum with or without combinations of 100 ng/ml r-IL-24, 10 mg/ml LPS, 10 mM SB 203580 and 100 mM theophylline and stained at day 4 (white histograms) and day 7 (black histograms). (c) Samples from patients 6, 18 and 25 were transfected with control or Mda-7/IL-24-specific siRNA and cultured with or without 100 ng/ml r-IL-24 or 10 mg/ml LPS and stained at day 7 with Apo 2.7 Ab. Histograms: White: control siRNA. Black: Mda-7/IL-24 siRNA.
Hatched: Mda-7/IL-24 siRNA þ LPS. Dotted: Mda-7/IL-24 siRNA þ r-IL-24.
